Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men

Michael Trifiro, J. Kellogg Parsons, Kerrin Palazzi-Churas, Jaclyn Bergstrom, Charles Lakin, Elizabeth Barrett-Connor

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Study Type - Prognosis (inception cohort) Level of Evidence 2b Objective To evaluate serum sex steroid hormone concentrations and long-term risk of subsequent lower urinary tract symptoms (LUTS) in a cohort of community-dwelling older men. SUBJECTS AND METHODS Between 1984 and 1987, serum sex hormone concentrations were measured in participants in the Rancho Bernardo Study, a prospective, community-based study. In 2006, the American Urological Association Symptom Index (AUA-SI) was mailed to surviving male participants. Logistic regression was used to examine associations of baseline hormone concentrations with AUA-SI. Results Among 158 surviving men with complete data and no history of prostate cancer, the mean (sd) age at serum sex steroid assessment was 58 (6.6) years with a mean (sd) follow-up of 20.3 (0.6) years. In age-adjusted logistic regression, there was a significant inverse association of testosterone : dihydrotestosterone (DHT) with LUTS (P = 0.05). Also, men with higher concentrations of bioavailable testosterone had a 56% decreased risk of LUTS compared with those with hypogonadal concentrations, although the association was not statistically significant (odds ratios 0.44, 95% confidence interval 0.14-1.40) or distributed evenly among quartiles. There were no significant associations of total testosterone, oestradiol (E2), testosterone : E2, DHT, or dehydroepiandrosterone with LUTS or with any measured hormones and urinary bother. Conclusions In this cohort, men with higher mid-life levels of testosterone : DHT and bioavailable testosterone had a decreased 20-year risk of LUTS. These data support other studies reporting inverse associations of serum testosterone with LUTS. Clinical trials of testosterone therapy should include LUTS and clinical benign prostatic hyperplasia as outcomes.

Original languageEnglish (US)
Pages (from-to)1554-1559
Number of pages6
JournalBJU International
Volume105
Issue number11
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Independent Living
Lower Urinary Tract Symptoms
Gonadal Steroid Hormones
Testosterone
Serum
Dihydrotestosterone
Logistic Models
Hormones
Dehydroepiandrosterone
Prostatic Hyperplasia
Estradiol
Prostatic Neoplasms
Odds Ratio
Steroids
Clinical Trials
Prospective Studies
Confidence Intervals

Keywords

  • Benign prostatic hyperplasia
  • Hormones
  • Hypogonadism
  • Lower urinary tract symptoms
  • Testosterone

ASJC Scopus subject areas

  • Urology

Cite this

Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. / Trifiro, Michael; Parsons, J. Kellogg; Palazzi-Churas, Kerrin; Bergstrom, Jaclyn; Lakin, Charles; Barrett-Connor, Elizabeth.

In: BJU International, Vol. 105, No. 11, 06.2010, p. 1554-1559.

Research output: Contribution to journalArticle

Trifiro, M, Parsons, JK, Palazzi-Churas, K, Bergstrom, J, Lakin, C & Barrett-Connor, E 2010, 'Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men', BJU International, vol. 105, no. 11, pp. 1554-1559. https://doi.org/10.1111/j.1464-410X.2009.09090.x
Trifiro, Michael ; Parsons, J. Kellogg ; Palazzi-Churas, Kerrin ; Bergstrom, Jaclyn ; Lakin, Charles ; Barrett-Connor, Elizabeth. / Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. In: BJU International. 2010 ; Vol. 105, No. 11. pp. 1554-1559.
@article{1907baf825ce485a9a129fddd5972c08,
title = "Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men",
abstract = "Study Type - Prognosis (inception cohort) Level of Evidence 2b Objective To evaluate serum sex steroid hormone concentrations and long-term risk of subsequent lower urinary tract symptoms (LUTS) in a cohort of community-dwelling older men. SUBJECTS AND METHODS Between 1984 and 1987, serum sex hormone concentrations were measured in participants in the Rancho Bernardo Study, a prospective, community-based study. In 2006, the American Urological Association Symptom Index (AUA-SI) was mailed to surviving male participants. Logistic regression was used to examine associations of baseline hormone concentrations with AUA-SI. Results Among 158 surviving men with complete data and no history of prostate cancer, the mean (sd) age at serum sex steroid assessment was 58 (6.6) years with a mean (sd) follow-up of 20.3 (0.6) years. In age-adjusted logistic regression, there was a significant inverse association of testosterone : dihydrotestosterone (DHT) with LUTS (P = 0.05). Also, men with higher concentrations of bioavailable testosterone had a 56{\%} decreased risk of LUTS compared with those with hypogonadal concentrations, although the association was not statistically significant (odds ratios 0.44, 95{\%} confidence interval 0.14-1.40) or distributed evenly among quartiles. There were no significant associations of total testosterone, oestradiol (E2), testosterone : E2, DHT, or dehydroepiandrosterone with LUTS or with any measured hormones and urinary bother. Conclusions In this cohort, men with higher mid-life levels of testosterone : DHT and bioavailable testosterone had a decreased 20-year risk of LUTS. These data support other studies reporting inverse associations of serum testosterone with LUTS. Clinical trials of testosterone therapy should include LUTS and clinical benign prostatic hyperplasia as outcomes.",
keywords = "Benign prostatic hyperplasia, Hormones, Hypogonadism, Lower urinary tract symptoms, Testosterone",
author = "Michael Trifiro and Parsons, {J. Kellogg} and Kerrin Palazzi-Churas and Jaclyn Bergstrom and Charles Lakin and Elizabeth Barrett-Connor",
year = "2010",
month = "6",
doi = "10.1111/j.1464-410X.2009.09090.x",
language = "English (US)",
volume = "105",
pages = "1554--1559",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men

AU - Trifiro, Michael

AU - Parsons, J. Kellogg

AU - Palazzi-Churas, Kerrin

AU - Bergstrom, Jaclyn

AU - Lakin, Charles

AU - Barrett-Connor, Elizabeth

PY - 2010/6

Y1 - 2010/6

N2 - Study Type - Prognosis (inception cohort) Level of Evidence 2b Objective To evaluate serum sex steroid hormone concentrations and long-term risk of subsequent lower urinary tract symptoms (LUTS) in a cohort of community-dwelling older men. SUBJECTS AND METHODS Between 1984 and 1987, serum sex hormone concentrations were measured in participants in the Rancho Bernardo Study, a prospective, community-based study. In 2006, the American Urological Association Symptom Index (AUA-SI) was mailed to surviving male participants. Logistic regression was used to examine associations of baseline hormone concentrations with AUA-SI. Results Among 158 surviving men with complete data and no history of prostate cancer, the mean (sd) age at serum sex steroid assessment was 58 (6.6) years with a mean (sd) follow-up of 20.3 (0.6) years. In age-adjusted logistic regression, there was a significant inverse association of testosterone : dihydrotestosterone (DHT) with LUTS (P = 0.05). Also, men with higher concentrations of bioavailable testosterone had a 56% decreased risk of LUTS compared with those with hypogonadal concentrations, although the association was not statistically significant (odds ratios 0.44, 95% confidence interval 0.14-1.40) or distributed evenly among quartiles. There were no significant associations of total testosterone, oestradiol (E2), testosterone : E2, DHT, or dehydroepiandrosterone with LUTS or with any measured hormones and urinary bother. Conclusions In this cohort, men with higher mid-life levels of testosterone : DHT and bioavailable testosterone had a decreased 20-year risk of LUTS. These data support other studies reporting inverse associations of serum testosterone with LUTS. Clinical trials of testosterone therapy should include LUTS and clinical benign prostatic hyperplasia as outcomes.

AB - Study Type - Prognosis (inception cohort) Level of Evidence 2b Objective To evaluate serum sex steroid hormone concentrations and long-term risk of subsequent lower urinary tract symptoms (LUTS) in a cohort of community-dwelling older men. SUBJECTS AND METHODS Between 1984 and 1987, serum sex hormone concentrations were measured in participants in the Rancho Bernardo Study, a prospective, community-based study. In 2006, the American Urological Association Symptom Index (AUA-SI) was mailed to surviving male participants. Logistic regression was used to examine associations of baseline hormone concentrations with AUA-SI. Results Among 158 surviving men with complete data and no history of prostate cancer, the mean (sd) age at serum sex steroid assessment was 58 (6.6) years with a mean (sd) follow-up of 20.3 (0.6) years. In age-adjusted logistic regression, there was a significant inverse association of testosterone : dihydrotestosterone (DHT) with LUTS (P = 0.05). Also, men with higher concentrations of bioavailable testosterone had a 56% decreased risk of LUTS compared with those with hypogonadal concentrations, although the association was not statistically significant (odds ratios 0.44, 95% confidence interval 0.14-1.40) or distributed evenly among quartiles. There were no significant associations of total testosterone, oestradiol (E2), testosterone : E2, DHT, or dehydroepiandrosterone with LUTS or with any measured hormones and urinary bother. Conclusions In this cohort, men with higher mid-life levels of testosterone : DHT and bioavailable testosterone had a decreased 20-year risk of LUTS. These data support other studies reporting inverse associations of serum testosterone with LUTS. Clinical trials of testosterone therapy should include LUTS and clinical benign prostatic hyperplasia as outcomes.

KW - Benign prostatic hyperplasia

KW - Hormones

KW - Hypogonadism

KW - Lower urinary tract symptoms

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=77952192447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952192447&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2009.09090.x

DO - 10.1111/j.1464-410X.2009.09090.x

M3 - Article

C2 - 20002438

AN - SCOPUS:77952192447

VL - 105

SP - 1554

EP - 1559

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 11

ER -